Mike Polark

Stock Analyst at Baird

(3.49)
# 929
Out of 5,044 analysts
76
Total ratings
53.06%
Success rate
5.48%
Average return

Stocks Rated by Mike Polark

iRhythm Technologies
Oct 10, 2025
Maintains: Outperform
Price Target: $180$220
Current: $182.84
Upside: +20.32%
Medtronic
Jun 30, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $93.23
Upside: -
Beta Bionics
May 30, 2025
Initiates: Outperform
Price Target: $20
Current: $24.43
Upside: -18.13%
LivaNova
May 20, 2025
Upgrades: Outperform
Price Target: $60
Current: $53.86
Upside: +11.40%
Insulet
May 13, 2025
Upgrades: Outperform
Price Target: $350
Current: $324.43
Upside: +7.88%
Inspire Medical Systems
May 6, 2025
Maintains: Outperform
Price Target: $230$236
Current: $77.16
Upside: +205.86%
Kestra Medical Technologies
Mar 31, 2025
Initiates: Outperform
Price Target: $29
Current: $27.98
Upside: +3.65%
Edwards Lifesciences
Jan 16, 2025
Downgrades: Underperform
Price Target: $60
Current: $82.23
Upside: -27.03%
ResMed
Sep 18, 2024
Downgrades: Underperform
Price Target: $180
Current: $257.39
Upside: -30.07%
Zimmer Biomet Holdings
Sep 10, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $101.12
Upside: -
Initiates: Outperform
Price Target: $405
Current: $375.84
Upside: +7.76%
Maintains: Outperform
Price Target: $487$503
Current: $545.00
Upside: -7.71%
Upgrades: Peer Perform
Price Target: n/a
Current: $126.63
Upside: -
Downgrades: Peer Perform
Price Target: n/a
Current: $130.68
Upside: -
Initiates: Outperform
Price Target: $121
Current: $69.33
Upside: +74.53%
Initiates: Peer Perform
Price Target: n/a
Current: $15.11
Upside: -
Upgrades: Outperform
Price Target: $25
Current: $16.57
Upside: +50.88%
Upgrades: Outperform
Price Target: $165
Current: $146.40
Upside: +12.70%
Initiates: Outperform
Price Target: n/a
Current: $100.99
Upside: -
Initiates: Outperform
Price Target: $13
Current: $10.57
Upside: +23.05%
Initiates: Peer Perform
Price Target: $21
Current: $5.04
Upside: +316.67%
Maintains: Outperform
Price Target: $230$250
Current: $241.23
Upside: +3.64%
Initiates: Neutral
Price Target: $43
Current: $1.58
Upside: +2,613.62%